Ser345
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser345  -  PARD6A (human)

Site Information
RGDGSGFsL______   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15714600

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 4 ) , mass spectrometry ( 1 , 2 , 5 , 6 , 8 ) , mutation of modification site ( 4 ) , phospho-antibody ( 4 ) , western blotting ( 4 )
Disease tissue studied:
breast cancer ( 2 , 6 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 , 2 ) , lung cancer ( 4 , 6 ) , non-small cell lung cancer ( 4 , 6 ) , non-small cell lung adenocarcinoma ( 4 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 4 ) , breast ( 1 , 2 ) , BT-20 (breast cell) ( 6 ) , BT-549 (breast cell) ( 6 ) , Calu 6 (pulmonary) ( 6 ) , H2009 (pulmonary) ( 6 ) , H2077 (pulmonary) ( 6 ) , H2887 (pulmonary) ( 6 ) , H322M (pulmonary) ( 6 ) , HCC366 (pulmonary) ( 6 ) , HCC78 (pulmonary) ( 6 ) , HEK293T (epithelial) ( 4 ) , HeLa (cervical) ( 5 ) , HOP62 (pulmonary) ( 6 ) , HUES-9 ('stem, embryonic') ( 8 ) , K562 (erythroid) ( 5 ) , MDA-MB-231 (breast cell) ( 6 ) , MDA-MB-468 (breast cell) ( 6 ) , NCI-H1299 (pulmonary) ( 4 ) , NCI-H1395 (pulmonary) ( 6 ) , NCI-H157 (pulmonary) ( 6 ) , NCI-H1648 (pulmonary) ( 6 ) , NCI-H1666 (pulmonary) ( 6 ) , NCI-H2030 (pulmonary) ( 6 ) , NCI-H322 (pulmonary) ( 6 ) , NCI-H520 (squamous) ( 6 ) , PC9 (pulmonary) ( 6 )

Upstream Regulation
Regulatory protein:
SMURF1 (human) ( 4 ) , TGFBR1 (human) ( 4 )
Putative in vivo kinases:
PKCI (human) ( 4 ) , PKCZ (human) ( 4 )
Treatments:
siRNA ( 4 )

Downstream Regulation
Effects of modification on PARD6A:
protein degradation ( 4 )
Effects of modification on biological processes:
cell motility, induced ( 4 ) , cytoskeletal reorganization ( 4 )

Disease / Diagnostics Relevance
Relevant diseases:
non-small cell lung cancer ( 4 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

3

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

4

Gunaratne A, Thai BL, Di Guglielmo GM (2013) Atypical protein kinase C phosphorylates Par6 and facilitates transforming growth factor β-induced epithelial-to-mesenchymal transition. Mol Cell Biol 33, 874-86
23249950   Curated Info

5

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

6

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

7

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

8

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.